These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

493 related articles for article (PubMed ID: 22842366)

  • 1. Downregulation of gene MDR1 by shRNA to reverse multidrug-resistance of ovarian cancer A2780 cells.
    Zhang H; Wang J; Cai K; Jiang L; Zhou D; Yang C; Chen J; Chen D; Dou J
    J Cancer Res Ther; 2012; 8(2):226-31. PubMed ID: 22842366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversal of multidrug resistance by two nordihydroguaiaretic acid derivatives, M4N and maltose-M3N, and their use in combination with doxorubicin or paclitaxel.
    Chang CC; Liang YC; Klutz A; Hsu CI; Lin CF; Mold DE; Chou TC; Lee YC; Huang RC
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):640-53. PubMed ID: 16544145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reverse multidrug resistance in laryngeal cancer cells by knockdown MDR1 gene expression.
    Zhigang H; Qi Z; Jugao F; Xiaohong C; Wei Z; Hong W; Hu H; Na M; Zheng Y; Demin H
    J Otolaryngol Head Neck Surg; 2009 Aug; 38(4):440-8. PubMed ID: 19755084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo RNA interference-mediated ablation of MDR1 P-glycoprotein.
    Pichler A; Zelcer N; Prior JL; Kuil AJ; Piwnica-Worms D
    Clin Cancer Res; 2005 Jun; 11(12):4487-94. PubMed ID: 15958634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells.
    Li Z; Hu S; Wang J; Cai J; Xiao L; Yu L; Wang Z
    Gynecol Oncol; 2010 Oct; 119(1):125-30. PubMed ID: 20624637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma.
    Ma JJ; Chen BL; Xin XY
    Eur J Obstet Gynecol Reprod Biol; 2009 Oct; 146(2):222-6. PubMed ID: 19758744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Establishment of hepatocellular carcinoma multidrug resistant monoclone cell line HepG2/mdr1.
    Chen YB; Yan ML; Gong JP; Xia RP; Liu LX; Li N; Lu SC; Zhang JG; Zeng DB; Xie JG; Yang JY; Yan LN
    Chin Med J (Engl); 2007 Apr; 120(8):703-7. PubMed ID: 17517188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of hypoxia on the chemotherapeutic sensitivity of human ovarian cancer cells to paclitaxel and its mechanism].
    Huang L; Zhang QH; Ao QL; Xing H; Lu YP; Ma D
    Zhonghua Zhong Liu Za Zhi; 2007 Feb; 29(2):96-100. PubMed ID: 17645840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The relationship between multi-drug resistance gene expression and drug resistance of ovarian carcinoma].
    Zhu L; Lang J; Shen K
    Zhonghua Fu Chan Ke Za Zhi; 1997 Aug; 32(8):462-6. PubMed ID: 9639738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interference with the expression of β-catenin reverses cisplatin resistance in A2780/DDP cells and inhibits the progression of ovarian cancer in mouse model.
    Zhao H; Wei W; Sun Y; Gao J; Wang Q; Zheng J
    DNA Cell Biol; 2015 Jan; 34(1):55-62. PubMed ID: 25211326
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting glucosylceramide synthase downregulates expression of the multidrug resistance gene MDR1 and sensitizes breast carcinoma cells to anticancer drugs.
    Sun Y; Zhang T; Gao P; Meng B; Gao Y; Wang X; Zhang J; Wang H; Wu X; Zheng W; Zhou G
    Breast Cancer Res Treat; 2010 Jun; 121(3):591-9. PubMed ID: 19693666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
    Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ
    Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversing drug resistance in the ovarian carcinoma cell line SKOV3/mdr1 in vitro by antisense oligodeoxynucleotides.
    Pan L; Tong Y; Jin Y; Zhou S; Zhang Y; Yang X; Mao N
    Chin Med J (Engl); 2001 Sep; 114(9):929-32. PubMed ID: 11780384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo reversal of P-glycoprotein-mediated multidrug resistance by efficient delivery of stealth RNAi.
    Xiao H; Wu Z; Shen H; Luo AL; Yang YF; Li XB; Zhu DY
    Basic Clin Pharmacol Toxicol; 2008 Oct; 103(4):342-8. PubMed ID: 18834355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of ovarian cancer chemotherapy by delivery of multidrug-resistance gene small interfering RNA using tumor targeting Salmonella.
    Deng J; Guo Y; Jiang Z; Yang M; Li H; Wang J
    J Obstet Gynaecol Res; 2015 Apr; 41(4):615-22. PubMed ID: 25370788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal of MDR1 gene-dependent multidrug resistance using short hairpin RNA expression vectors.
    Gan HZ; Zhang GZ; Zhao JS; Zhang FC; Bu LS; Yang SJ; Piao SL; Du ZW; Gao S; Zheng DM
    Chin Med J (Engl); 2005 Jun; 118(11):893-902. PubMed ID: 15978189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo reversal of multidrug resistance in a human leukemia-resistant cell line by mdr1 antisense oligodeoxynucleotides.
    Cucco C; Calabretta B
    Cancer Res; 1996 Oct; 56(19):4332-7. PubMed ID: 8813118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
    Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MDR1 siRNA loaded hyaluronic acid-based CD44 targeted nanoparticle systems circumvent paclitaxel resistance in ovarian cancer.
    Yang X; Iyer AK; Singh A; Choy E; Hornicek FJ; Amiji MM; Duan Z
    Sci Rep; 2015 Feb; 5():8509. PubMed ID: 25687880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticancer drugs induce mdr1 gene expression in recurrent ovarian cancer.
    Hille S; Rein DT; Riffelmann M; Neumann R; Sartorius J; Pfützner A; Kurbacher CM; Schöndorf T; Breidenbach M
    Anticancer Drugs; 2006 Oct; 17(9):1041-4. PubMed ID: 17001177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.